Relivion (neuromodulation system)

2021: Announcement of Relivion - neuromodulation systems for the treatment of migraine

In early March 2021, the company Neurolief introduced the Relivion non-invasive neuromodulation system for treatment. migraines This multichannel brain neuromodulation system brain is designed to treat acute migraine at home, taking into account the individual characteristics of the patient. The system completely stops migraine symptoms within 2 hours of application.

The headset stimulates six branches of the occipital and trigeminal nerves through three adaptive output channels. The action of the system is based on the release of neurotransmitters in the brain stem and the modulation of pain control. According to the developers, this is the only neuromodulation technology that has demonstrated statistically significant efficacy in a clinical trial of migraine.

Relivion neuromodulation system for migraine treatment released

Patients will now receive a highly effective, easy-to-use, non-invasive and medically free therapeutic option that will help them regain control of their lives, said principal investigator Stewart Tepper.

To prove the effectiveness of their system, the developers provided results from a multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial. According to the company, 46% of patients in the active therapy group did not experience migraine pains, while in the control group this proportion was only 11.8%. In the active therapy group, 75% of patients had the most unpleasant migraine symptoms (pain, photoblastness and nausea) completely stopped within two hours of treatment.

This is an important milestone for both Neurolief and the entire migraine therapy community. Relief offers a new treatment paradigm that reduces patients' reliance on pharmaceuticals and invasive procedures, said Neurolief Chairman Chris Richardson in a news release.[1]

Notes